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is usually corrected shortly after pregnancy and 
breastfeeding are complete [7].
Healthy premenopausal women experience a 
0.25–1% loss in BMD annually after reaching 
peak bone mass (commonly at the FN); how-
ever, no link has been established between this 
gradual loss in BMD and fracture risk in healthy 
women. Low Z-scores (2.5 standard deviations 
below other young females) are seen in 0.5% of 
premenopausal women [3]. In Spanish women 
20–44 years of age, 0.34% will have osteoporosis 
at the LS and 0.17% will have osteoporosis at the 
FN based on BMD alone [1]. Overall, 50–90% 
of premenopausal women have a secondary cause 
for osteoporosis (e.g., eating disorders or gluco-
corticoid use, among others), with the remaining 
women diagnosed with idiopathic osteo porosis 
[8]. Fracture risk in premenopausal women with 
osteoporosis remains low due to the small baseline 
fracture risk in younger women. The incidence of 
fractures in females under the age of 35 years is 
more difficult to detect due to the low incidence 
of three fractures per 100,000 patient-years but is 
noted to increase to 21 per 100,000 patient-years 
in women aged 35–44 years [1]. Premenopausal 
fractures are associated with a 1.5- to 3-fold 
increase in the risk of postmenopausal fractures 
[3]. Fracture risk is doubled or tripled once a loss 
of 10% in BMD has occurred; however, treat-
ments resulting in a 5% increase in BMD may 
decrease fracture risk [9].
Premenopausal women referred to a bone dis-
ease referral program at a tertiary medical center 
were evaluated for secondary versus idiopathic 
osteoporosis [10]. A retrospective review of all 
Osteoporosis in younger women results from 
either a low peak bone mass, increased bone 
loss prior to menopause or both [1]. Peak bone 
mass is reached by 30 years of age with 90% of 
the development completed by 18 years of age 
[2]. For most women, bone mass remains stable 
until menopause, when the loss of estrogen in 
conjunction with aging is associated with a 
decline in bone mineral density (BMD). Fam-
ily history, gender and race are responsible for 
the majority of peak bone mass; however, diet 
and exercise behaviors are responsible for up to 
25%. Peak bone mass variations are genetic in 
60–70% of cases [3]. Osteoporosis is a disease 
of the bone, with effects including decreased 
BMD and increased risk of fractures, especially 
at the spine, hip and wrist [4]. The loss of bone 
results from an imbalance in bone formation by 
osteoblasts and bone resorption by osteoclasts. 
Most treatments for osteoporosis aim to adjust 
this imbalance [5]. In the case of premenopausal 
osteoporosis, secondary causes are responsible 
for at least half of cases [1]. Secondary causes are 
listed in Table 1 [1]. In the Michigan Bone Health 
Study, over 600 premenopausal women followed 
for 6 years showed varied changes in lumbar 
spine (LS) BMD but a 1.6% decrease in femoral 
neck (FN) BMD starting in a woman’s mid 20s 
[6]. Risk factors for low BMD in premenopausal 
women include low body weight, amenorrhea, 
lack of physical activity, smoking, low dietary 
calcium or vitamin D, personal or family his-
tory of fracture, pregnancy and Caucasian or 
Asian race [3]. Minimal bone loss is noted during 
pregnancy and breastfeeding; however, this loss 
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premenopausal women referred for fracture or 
low bone mass over 1 year (n = 61) was con-
ducted, and 39% were found to have idiopathic 
osteoporosis, while 49% of the 29 women with 
a history of low-trauma fracture had idiopathic 
osteoporosis. This is consistent with other mea-
sures in premenopausal women. Low-trauma 
fracture was defined as that occurring due to 
a fall from standing height or less, with the 
exception of digit or skull fracture. Over half 
of the women (57%) reported a family history 
of osteoporosis. Secondary osteoporosis was due 
to amenorrhea in 34%, anorexia nervosa (AN) 
in 16%, glucocorticoid use in 13% and celiac 
disease in 10%. Premenopausal women with 
secondary osteoporosis had lower BMD at the 
spine (Z-score: -2.39 vs -1.58; p = 0.001) and 
hip than those with idiopathic osteoporosis, 
indicating a greater need for treatment in those 
women with secondary causes. Of the women 
referred due to a fracture, 28% did not have 
a low BMD. Bisphosphonates were used by 
47% of women with low BMD but no history 
of fracture and by 50% of women with idio-
pathic osteoporosis, which may indicate overuse 
of osteoporosis treatments in this population. 
Therefore, a need to clarify the role of osteo-
porosis treatments in younger, premenopausal 
women is needed.
The purpose of this review is to describe the 
available evidence for osteoporosis treatments 
in young and premenopausal women (Table 2).
Diagnosis
The International Society for Clinical Densito-
metry has developed standards for measuring 
BMD in premenopausal women [11]. They advo-
cate the use of Z-scores rather than T-scores 
(used in postmenopausal women to describe 
standard deviations from a young, normal 
female BMD), with Z-scores of less than -2.0 
at the LS or femur to determine BMD “below 
the expected range for age.” The Z-score com-
bined with risk factors including a history of 
fragility fracture is then used to make a diag-
nosis of osteoporosis in this younger cohort. In 
addition to BMD, a full medical history, fam-
ily history, menstrual history, diet and exercise, 
lifestyle, medication history and laboratory 
workup should be  performed to determine the 
u nderlying cause [1,3].
The US Preventive Services Task Force does 
not recommend BMD screening in healthy 
premenopausal women with no risk factors 
for osteoporosis [3]. Women with AN or with 
amenorrhea over 6 months to a year are recom-
mended to obtain BMD screening, although the 
results should be interpreted carefully, as many 
of these young women have yet to reach peak 
bone mass [9].
Osteoporosis prevention in young 
women
The National Osteoporosis Foundation recom-
mends that women aged 18–50 years should con-
sume 1000 mg of calcium and 600 IU of vitamin 
D daily [2]. Regular weight-bearing exercise is 
also associated with increased BMD. Other rec-
ommended lifestyle factors are to avoid smoking 
and alcohol, and limit caffeine consumption.
A 2013 systematic review of calcium intake 
and its effects on bone health concluded that 
data supporting the benefits in premenopausal 
women were limited, although positive effects 
on BMD were found in children and post-
menopausal women [12]. In comparison, calcium, 
vitamin D and increased physical activity dem-
onstrated a positive effect in 16 premenopausal 
women (average age 36 years) with idiopathic 
osteoporosis [13]. All secondary causes of osteopo-
rosis were excluded. The study design was obser-
vational and followed women over an average 
of 3 years. The subjects were instructed to take 
calcium 500–1000 mg/day based on dietary cal-
cium intake, take vitamin D 400–800 IU/day, 
increase physical activity and avoid smoking. 
The exact formulation and amount of calcium, 
vitamin D and type and amount of exercise 
for each subject was not reported. Half of the 
Table 1. Secondary causes of osteoporosis in young women.
Causes Examples
Medications Glucocorticoids, anticonvulsants, aromatase 
inhibitors, heparin, alcohol, LHRH agonists, 
medroxyprogesterone acetate, high-dose 
levothyroxine, cytotoxic chemotherapy
Endocrine diseases Hypogonadism, hyperthyroidism, Cushing’s 
disease, growth hormone deficiency, 
hypopituitarism, hyperparathyroidism, Type 1 
diabetes
Malnutrition or malabsorption Anorexia nervosa, inflammatory intestinal 
disease, celiac disease, intestinal resection
Inflammatory disease Rheumatoid arthritis, systemic lupus 
erythematous
Transplant patients Solid organ and bone marrow transplants
Other causes Liver disease, osteogenesis imperfecta, 
HIV infection, hemochromatosis, idiopathic 
osteoporosis, pregnancy, systemic 
mastocytosis, chronic kidney disease, 
malignancies, hyperprolactinemia, multiple 
myeloma, depression
LHRH: Luteinizing hormone-releasing hormone. 
Data taken from [1,3].
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women had a family history of osteoporosis 
and 25% had experienced a fragility fracture. 
Nearly 40% of the subjects had low calcium 
intake (less than 500 mg/day) at baseline and 
five patients smoked. Z-scores at baseline were 
-2.04 at the LS and -1.47 at the FN, meeting the 
definition for low bone mass. Over half of the 
women increased their calcium intake through 
diet rather than supplementation. All subjects 
reported an increase in physical activity. A sig-
nificant 1.9% increase was seen in LS BMD after 
2 years (p = 0.021) and a 5.6% increase was seen 
at the FN after 3 years (p = 0.04). The significant 
increase at the FN is sufficient to reduce fracture 
risk. No fractures were found during the study 
period. This is the only study evaluating the 
impact of treatment in idiopathic osteoporosis 
and demonstrates that lifestyle changes can have 
a significant impact on bone health.
A meta-ana lysis of resistance exercise on BMD 
in premenopausal women did not find a statisti-
cally significant difference in LS or FN BMD 
[14]. Walking, jumping and resistance exercises 
have demonstrated a 1.2–2.6% increase in FN 
BMD per year (p < 0.05), while resistance train-
ing and weight lifting demonstrated a 0.02% 
increase in spinal BMD (p < 0.05) in healthy pre-
menopausal women [15–17]. In a cohort study of 
premenopausal women with rheumatoid arthritis 
in Brazil (n = 71; average age: 38 years) with 
29 healthy controls, women who were sedentary 
were found to have a higher risk of osteopenia (no 
hazard ratio reported; p = 0.044), while women 
with moderate levels of activity had a relative risk 
of 0.53 (95% CI: 0.37–0.76) [18]. No fractures 
were reported during the 2-year course of the 
study. Women with rheumatoid arthritis may 
limit exercise due to pain and deformities asso-
ciated with the disease process. Overall, these 
results support the idea that an increase in exer-
cise as tolerated can have a positive impact on 
BMD in premenopausal women.
Treatment
The American Association of Clinical Endo crin-
ologists recommends the bisphosphonates alendro-
nate, risedronate and zoledronic acid, and deno-
sumab as first-line treatments for post menopausal 
osteoporosis [19]. Ibandronate is recommended 
as a second-line agent, raloxifene second or third 
line, and calcitonin as a last-line therapy. Teri-
paratide is recommended for women who have 
failed bisphosphonates or have very high fracture 
risk. Oral bisphosphonates are associated with 
gastrointestinal (GI) adverse effects, such as 
heartburn, indigestion and esophageal irritation. 
Intravenous (iv.) bisphosphonates are associated 
with flu-like symptoms (fever and muscle aches), 
especially with the first infusion in nearly one-
third of women. Osteonecrosis of the jaw (ONJ) 
is associated with bisphosphonate use, but is gen-
erally seen more often with iv. bisphosphonates 
at higher doses than those used for osteoporosis. 
Nausea and orthostatic hypotension have been 
experienced with those women using teripara-
tide. Calcitonin injections may be accompanied 
by nausea, local reactions, sweating and flushing.
Consideration of the risks of osteoporosis 
treatment in premenopausal women must also 
include risks for those women who are pregnant 
or breastfeeding. Concerns for placental transfer 
of bisphosphonates have resulted from rat studies 
of fetal skeletal development and hypocalcemia. 
Most case reports in humans have found no con-
genital abnormalities; however, bisphosphonates 
carry a US FDA category C pregnancy risk, and 
use of bisphosphonates without contraception 
is not recommended in younger females [20]. 
Case reports of two women with osteogenesis 
imperfecta treated with bisphosphonates report 
hypocalcemia in one newborn and club feet in 
the other infant [10]. Concern also exists due to 
the long duration of bisphosphonate incorpora-
tion in the bone [3]. One case series consisting 
of four infants born to three mothers (one with 
osteogenesis imperfecta and two with polyostotic 
fibrous dysplasia) who received iv. pamidronate 
prior to conception did not find any adverse 
maternal or fetal effects [21]. The FDA pregnancy 
risk for teriparatide is category C and iv. zole-
dronic acid is category D [3]. Selective estrogen 
receptor modulators (SERMs) should not be 
used in premenopausal women due to increased 
bone loss [8]. Although use of oral contraceptives 
have demonstrated mixed results in BMD of pre-
menopausal women, the American College of 
Rheumatology no longer recommends estrogen 
as a treatment of osteo porosis in pre- or post-
menopausal women [22,23]. It is important to note 
potential limitations when evaluating choice of 
drug therapy based on the FDA pregnancy risk 
categories. The successive categories can be mis-
leading and it may appear that there is increasing 
risk of severity of mal formation between catego-
ries. Furthermore, there is no distinction between 
source of data (i.e., animal versus human) within 
each category. The FDA pregnancy category 
classification scheme also does not address that 
the lack of treatment of certain comorbid condi-
tions (e.g., diabetes mellitus, pregnancy-induced 
hypertension and asthma) may outweigh the risk 
of drug exposure to the fetus [24].
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Anorexia nervosa
In women with AN, 20–50% develop osteo-
porosis and 44% experience a fracture [9,25]. 
The development of amenorrhea with AN leads 
to a decrease in estrogen and bone loss within 
12 months. Restoring body weight is the primary 
treatment for osteoporosis associated with AN, 
while recommending exercise may prove harmful 
in those who have used exercise to purge. Most 
studies of osteoporosis in AN have focused on 
the replacement of estrogen as a treatment strat-
egy. Bisphosphonate treatment in women with 
a history of purging may be limited due to the 
potential for esophageal ulcer development.
In an observational study of 75 women with 
AN, the average age of included subjects was 
24 years with a spine T-score of -1.8 and a hip 
T-score of -1.4 [26]. Calcium and vitamin D 
intake were not analyzed. Women were followed 
from 6 months to 5 years. In the 45 women 
who did not take oral contraceptives, resum-
ing a menstrual cycle was associated with an 
increase in spine BMD of 3.1% (p = 0.02), while 
an increase in weight (to greater than 85% of 
expected weight and/or a 10% increase) was 
associated with an increase in hip BMD of 
0.6% (p = 0.05). The use of oral contraceptives 
was not associated with a significant change in 
BMD at either site, whether or not weight was 
gained or menses resumed. The authors summa-
rized that weight restoration is more associated 
with an increase in hip BMD, while the return 
of menses is more associated with spinal BMD 
improvement.
Adolescents with AN were followed for 1 year 
after administration of hormone therapy to deter-
mine the medication’s effect on BMD (n = 38) 
[27]. Baseline BMD was measured for each 
woman after 1 year of amenorrhea and they were 
treated with ethinyl estradiol 50 µg/norgestrel 
0.5 mg daily. After 1 year, 22 women were avail-
able for analysis. The mean age at baseline was 
17 years and the LS BMD T-score was -2.1. Cal-
cium and vitamin D intake was not discussed. 
After 1 year, the LS T-score in treated women 
was -1.8; however, this was not  significantly 
 different from baseline.
In a longitudinal study of 45 women with AN, 
women with a T-score less than -2.5 were treated 
with 17-b estradiol 0.5 mg percutaneously for 
days 1–21 of each cycle and dydrogesterone 
10 mg on days 11–21 for 2 years (n = 12) [25]. The 
mean age of women was 25 years, and those with 
osteoporosis had AN for 8 years, amenorrhea 
for 7 years and Z-scores at LS of -2.3, FN -3.4 
and total hip -3.4. Calcium and vitamin D were 
only given to those with noted deficiencies. No 
significant changes in BMD were found at any 
site in either the treatment or control group, and 
there were no differences between the groups. 
Although hormone therapy did not result in a 
change in BMD, weight increase at 1 year did 
result in a significant increase in LS and total hip 
BMD (p = 0.04 for both), as well as a return of 
the menstrual cycle at the spine, total hip and FN 
(4%, p = 0.008; 3%, p = 0.05; and 3%, p = 0.04, 
respectively). This study further demonstrates 
the benefit of weight gain and return of menses 
in women with AN. Hormone therapy did not 
demonstrate a benefit, even in those women with 
very low BMD.
An observational study of 50 women with AN 
(average age: 16 years) demonstrated no benefit 
of hormone therapy for increasing BMD [28]. 
Women with anorexia were given the option, 
along with their treatment team and family, of 
standard treatment for AN (n = 28) or standard 
treatment plus an oral contraceptive to prevent 
bone loss (n = 22). Standard treatment involved 
medical, nutritional and psychiatric approaches. 
Five different oral contraceptives were used in 
the women. All women received a multivitamin 
with 400 IU of vitamin D daily and calcium 
1200–1500 mg daily was given to those women 
without adequate dietary calcium intake. At 
baseline, women had experienced amenorrhea 
for an average of 16 months and had a LS Z-score 
of -1.58 and a FN T-score of -1.58 (Z-score not 
reported). A significant difference between 
the groups at baseline was a longer duration 
of AN in the oral contraceptive group (15.7 vs 
29.8 months; p = 0.02). After 1 year, women in 
both groups gained 3–4 kg on average. How-
ever, no significant change in BMD at either the 
LS or FN was observed. The authors note that 
use of oral contraceptives in the absence of clear 
benefit for BMD may mask the natural return 
of menses that is often used to mark progress in 
treating AN.
Another study evaluating the effect of estro-
gen/progesterone on BMD in young women 
with AN randomized 48 women with amenor-
rhea to active drug (n = 22) or placebo (n = 26) 
for 18 months. The mean age of the subjects 
was 24 years. After 18 months, no difference 
was found between the BMD of either group 
[29]. Those who resumed menses had a 19.3% 
increase in BMD. They also noted that women 
with a lower weight at baseline had less recovery 
in their bone mass. This study further supports 
the role of weight gain and menses recovery over 
hormone therapy in women with AN.
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A randomized, double-blind, placebo-con-
trolled study of a triphasic oral contraceptive 
in females with AN demonstrated a significant 
change in LS BMD at 6 months; however, by the 
conclusion of the study at 13 months, the differ-
ence was no longer significant [30]. Young women 
were randomized to norgestimate/ethinyl estra-
diol (n = 53) or placebo (n = 59). The average 
age of subjects included was 15 years and they 
took a multivitamin with 500-mg calcium and 
400-IU vitamin D. The baseline LS Z-score was 
-0.8. After six cycles, the change in BMD at the 
LS was 2.4% in the treatment group and 1% in 
the placebo group (p = 0.013). After 13 cycles, 
LS BMD was increased by 3.1% in the treat-
ment group and 2.4% in the placebo group 
(p = 0.268). There were no significant differences 
in hip BMD at any time point. For those in the 
treatment group, adverse events were reported as 
follows: dysmenorrhea: 16.4%, abdominal pain: 
11.5%, flu-like symptoms: 11.5% and sinusitis: 
11.5%. Although this trial was shorter than 
the others described, it demonstrates a possible 
early benefit for hormone therapy on BMD but 
no long-term benefit. With the development of 
adverse events in several women, the risks of hor-
mone therapy in these women likely outweigh 
any potential benefit.
Overall, the evidence does not suggest a 
benefit for estrogen or progesterone therapy in 
young women with AN. Calcium and vitamin 
D consumption was not analyzed in the major-
ity of the trials; however, incorporating lifestyle 
changes into the treatment of AN may prove ben-
eficial. Other osteoporosis treatments have not 
been evaluated in this population. The strongest 
evidence for improvement of BMD in women 
with AN is for weight gain and return of the 
menstrual cycle.
Breast cancer
Breast cancer treatment with gonadotropin-
releasing hormone analogs, tamoxifen and 
aromatase inhibitors are associated with bone 
loss [31]. Use of these medications results in a 
hypo gonadal state in women and contributes 
to accelerated bone loss of up to 13% within 
the first year of treatment, which is often more 
severe than age-related bone loss. Studies have 
estimated the bone loss to be 3–8% in the 
LS and 2–4% in the total hip [32]. Although 
tamoxifen is associated with increases in BMD 
for postmenopausal women, it is associated with 
a decrease in LS and hip BMD in premeno-
pausal women due to its antagonistic effects 
at the bone in the presence of premenopausal 
estrogen. Bisphosphonates have been evaluated 
in this population for the prevention of bone 
loss associated with breast cancer treatments. 
Increased concerns exist for the development of 
ONJ in cancer patients receiving bisphospho-
nates beyond that of women with osteoporosis. 
A systematic review reported 6–10% of cancer 
patients receiving bisphosphonates may develop 
ONJ over 2–3 years [33]. The Belgian Bone Club 
recommends that breast cancer patients treated 
with aromatase inhibitors be treated with zole-
dronic acid 4 mg every 6 months [31]. Raloxifene 
is not recommended in women with a history of 
breast cancer who have been treated with tamox-
ifen due to cross-resistance [34]. Estrogens and 
teriparatide are also not recommended by the 
ASCO due to their potential to increase cancer 
or metastases.
An open-label trial evaluating the effect of 
zoledronic acid 4 mg iv. every 6 months in pre-
menopausal women over age 40 (mean age: 
44–45 years) who were undergoing chemother-
apy for breast cancer (n = 112) was conducted 
to evaluate the effect on BMD [35]. All women 
took calcium 500 mg and vitamin D 1000 IU 
daily. At baseline, the LS BMD was 1.09 g/cm2 
and FN BMD was 0.88 g/cm2. After 12 months, 
LS BMD decreased 1.1% in the zoledronic acid 
group (n = 56) and by 7.5% in the observation 
group (n = 56; p < 0.001 between groups), and 
FN BMD increased by by 1.1% in the zoledronic 
acid group and decreased by 3.4% in the obser-
vation group (p < 0.001 between groups). The 
only adverse events reported were chills, arth-
ralgia and myalgia in the zoledronic acid group 
at the time of infusion. Although not a random-
ized controlled trial (RCT), these results suggest 
a benefit for zoledronic acid in preserving LS 
BMD and improving FN BMD in women with 
breast cancer.
An additional, open-label, Phase III trial 
evaluated the impact of zoledronic acid on bone 
loss in premenopausal women (average age: 
44–46 years) receiving treatment for hormone-
responsive breast cancer [36]. The Austrian Breast 
and Colorectal Cancer Study Group Trial 12 
examined the use of goserelin in combination 
with aromatase inhibitors. Goserelin is associ-
ated with a 5% BMD loss in premenopausal 
women and aromatase inhibitors are also asso-
ciated with bone loss of 4–5% over 2 years. The 
BMD substudy was performed to evaluate the 
effects of combination treatment on bone health 
and the impact of prevention on expected bone 
loss. Premenopausal women (n = 401) were ran-
domized to goserelin plus tamoxifen or goserelin 
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plus anastrazole for 3 years. Each group was then 
further randomized to those who would receive 
zoledronic acid 4 mg iv. every 6 months (n = 204) 
or not (n = 197). Calcium and vitamin D were 
not discussed by the authors. At baseline, the 
LS BMD was 1.0 g/cm2 and the hip BMD was 
0.7 g/cm2. Women who did not receive zole-
dronic acid experienced significant bone loss in 
the LS over 3 years (-14.4%; p < 0.001), with a 
T-score drop of -1.4; however, those who received 
zoledronic acid did not demonstrate a significant 
change in LS BMD over 3 years. Infusion reac-
tions were the most commonly reported adverse 
effect of zoledronic acid therapy and most often 
occurred during the first infusion. Bone pain 
was reported in 36%, arthralgia in 28% and 
fever in 11% of women who received zoledronic 
acid (p = 0.0003, p = 0.12 and p < 0.001, respec-
tively compared with placebo). There were no 
reports of ONJ or fractures for any women in the 
trial. A follow-up was conducted 2 years after the 
completion of the study (5 years from baseline), 
and women who did not receive zoledronic acid 
had continued declines in BMD, with a total of 
6.6% loss at the LS (p < 0.01 from baseline) [37]. 
Those in the zoledronic acid group saw a 4% 
increase in LS BMD (p = 0.02) at the 60-month 
mark. Two fractures were reported by women in 
the placebo group, with none in the zoledronic 
acid group; however, this was not statistically 
significant (p = 0.242). In women at risk for 
osteoporosis while being treated for breast can-
cer, the use of zoledronic acid for bone protection 
was supported by evidence of stable BMD over 
5 years compared with a sharp decline in the 
placebo group.
Zoledronic acid was also evaluated for pro-
phylaxis of bone loss in women receiving che-
motherapy for breast cancer [32]. The iv. route 
is preferred to minimize the GI adverse effects 
of oral bisphosphonates in women receiving 
chemo therapy. Premenopausal women with new 
diagnoses of breast cancer were randomized to 
zoledronic acid 4 mg iv. every 3 months (n = 50) 
or placebo (n = 53) for 1 year while receiving 
chemotherapy. The average age of participants 
was 42 and all were given calcium 1000 mg daily 
and vitamin D 400–800 IU daily. At baseline, 
LS Z-scores were 0.2, FN Z-scores were 0.15 and 
hip Z-scores were 0.17–0.25. After 12 months, 
women in the placebo group experienced a 
4.39% decrease in LS BMD compared with 
0.6% in the zoledronic acid group (p < 0.05). 
Similar results were seen for the FN (1.5% loss 
in the placebo group compared with a gain of 
0.4% in the zoledronic acid group; p < 0.05) and 
total hip (2.8 gain vs -0.12% loss, respectively; 
p < 0.05). There were no reports of renal failure 
or ONJ with bisphosphonate therapy; however, 
47% complained of eye discomfort, which was 
significantly different from placebo (p < 0.01). A 
follow-up study of the women 12 months with 
no intervention after the original study demon-
strated significant continued bone loss in the fol-
lowing year at the LS and total hip for women 
who received placebo (p < 0.001 for both) but 
remained stable for those who had received zole-
dronic acid [38]. This study further describes the 
benefit of zoledronic acid for osteoporosis pre-
vention in women undergoing chemotherapy 
for breast cancer. Adverse events experienced by 
women in this population are similar to those 
experienced by postmenopausal women.
Risedronate was evaluated for the preven-
tion of bone loss in premenopausal women with 
breast cancer in a placebo-controlled, double-
blind, randomized, Phase II trial of 216 women 
(mean age: 43 years) [39]. All patients received 
calcium 600 mg and vitamin D 400 IU daily. 
Premenopausal women preparing to undergo 
chemotherapy for breast cancer were random-
ized to risedronate 35 mg weekly (n = 108) 
or placebo (n = 108) for 1 year. LS BMD at 
baseline was 1.2 g/cm2. At 1 year, the change in 
BMD at the LS was -4.3% for risedronate and 
-5.4% for placebo; however, the difference was 
not statistically significant. Adverse events were 
similar in both groups. This differs from stud-
ies in postmenopausal women where risedronate 
demonstrated an increase in BMD in women 
with breast cancer undergoing chemotherapy 
[40,41]. Another trial evaluating risedronate in 
53 women with breast cancer and ovarian fail-
ure randomized women to risedronate 30 mg 
daily for 2 weeks every 12 weeks for 2 years 
(n = 27) or placebo (n = 26) [42]. After 2 years, 
the BMD decreased in the placebo group but 
increased in the risedronate group for a differ-
ence of 2.5% at the LS (p = 0.041) and 2.6% at 
the FN (p = 0.029). Although these studies have 
mixed results, overall, the data for the benefit of 
risedronate are not as convincing as those for 
zoledronic acid.
The overall data for breast cancer support the 
role of bisphosphonates (particularly iv. bisphos-
phonate zoledronic acid) for the prevention of 
osteoporosis associated with breast cancer treat-
ment in premenopausal women. The safety pro-
file in these women appears to be comparable 
with that for postmenopausal women, despite 
increased administration (every 6 months vs 
every year).
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Glucocorticoid-induced osteoporosis
In the setting of glucocorticoid use, BMD is 
noted to decrease precipitously after 3 months 
of treatment up to 6 months with a slower, con-
tinued decline thereafter [23]. Glucocorticoids 
contribute to osteoporosis by inhibiting osteo-
blast activity and decreasing calcium absorption 
in the GI tract. The 2010 American College of 
Rheumatology guidelines report an increased 
risk of fracture in patients who currently receive 
or in the past have received 2.5–7.5 mg daily of 
prednisone or its equivalent. Fractures are noted 
to develop in patients taking glucocorticoids 
regardless of BMD and may occur in premeno-
pausal women at higher BMDs than those seen 
in postmenopausal women. Recommendations 
are rated as follows: Level A (multiple RCTs or 
meta-analysis); Level B (single RCT or non-
randomized study); and Level C (expert consen-
sus or case series). The authors recommend that 
premenopausal women on glucocorticoid treat-
ment with history of a prevalent fragility frac-
ture should be treated for osteoporosis, with the 
exception of those of child-bearing potential on 
therapy for less than 3 months. They also recom-
mend that women with no child-bearing poten-
tial taking prednisone ≥5 mg or its equivalent 
daily for 1–3 months should take alendronate or 
risedronate (Level A and studied for 3–4 years); 
however those taking ≥7.5 mg or its equivalent 
should receive zoledronic acid (Level B, studied 
for 3 years) [43–45]. Those receiving glucocorti-
coid treatment for greater than 3 months may 
take alendronate or risedronate (Level A), zole-
dronic acid or teriparatide (Level B) [23]. Women 
with child-bearing potential taking prednisone 
≥7.5 mg or its equivalent daily for more than 
3 months should take alendronate (Level A), rise-
dronate or teriparatide (Level C). These thera-
pies were selected for their shorter half-lives. No 
recommendations are made for those taking less 
than 7.5 mg of prednisone or its equivalent for 
greater than 3 months. All women, regardless of 
dose or duration of glucocorticoid therapy, should 
take calcium 1200–1500 mg/day and vitamin D 
to achieve normal 25-hydroxyvitamin D levels, 
or 800–1000 IU daily. Glucocorticoid use may 
require the need for higher vitamin D doses in 
order to maintain normal levels. The authors 
noted a lack of data in premenopausal women 
that limited the strength and number of recom-
mendations. Alendronate and risedronate have 
data demonstrating both improvement in BMD 
and a decrease in vertebral fracture risk in patients 
with glucocorticoid-induced osteoporosis (GIO). 
The American College of Rheumatology (ACR) 
also recommends using the lowest dose of gluco-
corticoid for the shortest duration possible in 
order to minimize osteoporosis risk.
Following the revision of the ACR guidelines 
in 2010, a Joint Guideline Working Group was 
established by the International Osteoporosis 
Foundation (IOF) and the European Calcified 
Tissue Society (ECTS) to update GIO recom-
mendations for Europe. The Joint IOF–ECTS 
Working Group provided a framework for the 
use of oral glucocorticoid therapy at any dose 
for a period of 3 months or longer in male and 
female patients aged 18 years and older [46]. Simi-
lar to the ACR guidelines, the Joint IOF–ECTS 
Working Group position statement discussed epi-
demiology and pathophysiology of GIO as well 
as the Fracture Risk Assessment Tool (FRAX®, 
WHO, Sheffield, UK [101]). The Working Group 
recommended alendronate, etidronate, risedro-
nate, zoledronic acid and teriparatide as first-line 
therapies for GIO in the majority of patients. 
Even though recommendations from the ACR 
were discussed in this position statement by the 
IOF and the ECTS, the document explicitly 
stated that local factors specific to each country 
should be taken into account when considering 
intervention.
As the evidence for each of the agents is well 
established and supported by the guidelines, 
trials that compare the various treatments are 
reviewed below.
Infused versus oral bisphosphonates were 
compared among different age groups and 
menopausal state in a post hoc analysis of a trial 
comparing zoledronic acid and risedronate [47]. 
The authors felt that adherence would be greater 
with an iv. infusion than with an oral medica-
tion and thus the chance of fractures may be 
reduced [48]. Subjects ranging in age from 18 to 
85 years with or at risk for GIO (taking pred-
nisone 7.5 mg or equivalent daily) were random-
ized to zoledronic acid 5 mg iv. once or risedro-
nate 5 mg by mouth daily for 1 year. Pregnant 
women or those not using contraception were 
excluded. All subjects also received calcium 
1000 mg and vitamin D 400–1200 IU daily. At 
baseline, 86 women aged less than 35 years and 
231 women aged 35–50 years were included. For 
menopausal state, 195 premenopausal women 
were included. Baseline LS T-score was -1.3 to 
-1.4 in the treatment group and -0.9 in the at-
risk group. BMD was assessed at baseline and at 
12 months, and was found to be increased at the 
LS in women aged 35–50 years, with GIO more 
for zoledronic acid than risedronate (p = 0.0041). 
No significant difference was found in LS BMD 
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in women less than 35 years of age. The authors 
report that this may be due to the low sample 
size of women in this age range (n = 86 out of 
833 total). In the subgroup of premenopausal 
women with GIO, zoledronic acid increased LS 
BMD by 3.1% compared with 1.7% by rise-
dronate, and in premenopausal women at risk 
for GIO, zoledronic acid increased LS BMD by 
1.8% compared with 0.7% by risedronate; how-
ever, these findings did not reach statistical sig-
nificance. Total hip BMD increased significantly 
more in the zoledronic acid group compared with 
risedronate, both in women with GIO and those 
at risk for GIO (1.34%; p = 0.025 and 1.45%; 
p = 0.049, respectively). Differences between the 
groups appeared at 6 months. The sponsor of the 
study and manufacturer of zoledronic acid was 
involved in all aspects of the design, data collec-
tion and reporting of results. In all HORIZON 
(Health Outcomes and Reduced Incidence with 
Zoledronic acid ONce yearly) participants, five 
vertebral fractures developed in the zoledronic 
acid group and three in the risedronate group; 
however, the difference was not significant. No 
cases of ONJ were reported during the study. 
Adverse events were more common in the zole-
dronic acid group than the risedronate group 
overall in both the treatment and prevention 
groups (p = 0.0159 and 0.0272, respectively). 
The significant zoledronic acid adverse reactions 
included pyrexia 12–15%, myalgia 6–11%, vom-
iting 2–6%, influenza-like illness 6–7%, muscu-
loskeletal chest pain 1–3%, sciatica 2–3% and 
chills 2–4%. Overall, participants preferred the 
iv. route for both convenience (81%) and satis-
faction (78%). Based on the results of this large, 
well-designed trial, zoledronic acid was superior 
to risedronate at the hip and well tolerated in 
younger women with GIO.
Alendronate was compared with activated 
vitamin D in 201 patients with GIO over 
18 months in a randomized, double-blind, dou-
ble-dummy study [49]. Participants were included 
if they planned to start or had started prednisone 
7.5 mg or its equivalent daily within the previ-
ous 12 weeks and anticipated to stay on therapy 
for at least 6 months due to a rheumatic condi-
tion. Subjects were randomized to alendronate 
10 mg daily (n = 99) and alfacalcidol 1 µg daily 
(n = 101), including seven and ten premeno-
pausal women, respectively. The average age of 
those in the study was 61 years with prednisone 
doses of 22–23 mg/day. All subjects took cal-
cium 1000 mg and vitamin D 400 IU daily. At 
baseline, FN T-scores demonstrated low bone 
mass (-1.2 to -1.4). After 18 months, LS BMD 
increased by 2.1% in the alendronate group and 
declined by 1.9% in the alfacalcidol group, with 
an absolute difference of 4% (95% CI: 2.4–5.5), 
while hip BMD increased by 1.4% in the alen-
dronate group and declined by 2.0% in the alfa-
calcidol group, for an absolute difference of 3.4% 
(95% CI: 1.3–5.5). Over the course of the study, 
three vertebral fractures developed in the alendro-
nate group compared with 13 in the alfacalcidol 
group (hazard ratio: 0.4; 95% CI: 0.1–1.4). Other 
fractures occurred in two alendronate subjects 
and three alfacalcidol subjects (hazard ratio: 0.7; 
95% CI: 0.1–4). Adverse events were similar in 
both groups, including GI complaints and hypo-
calcemia. This study definitively proves the supe-
riority of GIO treatment with bisphosphonates 
over that of activated vitamin D. Notably, this 
study demonstrated a reduction in fractures with 
bisphosphonate treatment.
The effects of teriparatide and alendronate on 
LS BMD were compared in a subset of 67 pre-
menopausal women (age: ≥21 years) with GIO 
from a total of 428 [50]. Men and postmenopausal 
women were also evaluated over 18 months. 
Subjects were included if they had taken ≥5-mg 
prednisone for ≥3 months and had a LS or hip 
BMD T-score ≤-2.0 or ≤-1.0 with one fragility 
fracture. Subjects were randomized to teripa-
ratide 20 µg subcutaneously daily (n = 37) or 
alendronate 10 mg by mouth daily (n = 30). 
Calcium 1000 mg daily and vitamin D 800 IU 
daily were also given over the course of the study. 
The average age of women in the alendronate 
group was 36 and 40 years in the teriparatide 
group, LS T-scores of -2.6 and -2.4, total hip 
T-scores of -1.8 and -1.7, and a history of daily 
prednisone use 10 and 8 mg for 0.9 and 1.8 years, 
with 28 and 33% having a history of fracture, 
respectively. Indications for glucocorticoid use 
included joint, autoimmune, respiratory and 
bowel diseases. Five women in the teriparatide 
group and nine women in the alendronate group 
discontinued from the study (p = 0.06); most dis-
continued due to adverse events or subjects’ deci-
sion to withdraw. Premenopausal women treated 
with teriparatide demonstrated a 7% increase in 
LS BMD compared with 0.7% in the alendronate 
group (p < 0.001) at 18 months. A 4% increase in 
hip BMD in the teriparatide group versus 1% in 
the alendronate group (p < 0.01) was also noted. 
The differences were significant at 6 months and 
maintained during the duration of the study. In 
the subjects treated with alendronate, LS BMD 
did not significantly differ from baseline at any 
time point in the study. No new vertebral frac-
tures were detected in any premenopausal women 
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during the study period. Two nonvertebral frac-
tures occurred in the teriparatide group and none 
in the alendronate group; however, the difference 
was not significant (p = 0.32). Adverse effects, 
including influenza (10%), back pain (17%), 
dyspnea (10%) and rash (10%), were reported 
in the alendronate group, and nausea (14%), 
influenza (11%), headache (11%), depression 
(8%), vomiting (14%), dyspepsia (8%), cough 
(8%) and myalgia (8%) were reported in the 
teri paratide group. The authors speculated that 
teriparatide demonstrated a greater impact on 
BMD in premenopausal women due to the 
mechanism of action directly altering the effects 
of glucocorticoids on bone, whereas alendronate 
does not mechanistically correct the effects of 
gluco corticoids in the presence of estrogen in pre-
menopausal women [5]. A final report was issued 
after 36 months of treatment [51]. Although not 
broken down by menopausal state, teriparatide 
continued to significantly improve BMD at the 
LS (11 vs 5.3%; p < 0.001), total hip (5.2 vs 2.7%; 
p < 0.001) and FN (6.3 vs 3.4%; p < 0.001) com-
pared with alendronate. A significant difference in 
vertebral fractures was also noted after 36 months, 
with 1.7% of participants in the teriparatide group 
experiencing a fracture and 7.7% of participants 
in the alendronate group experiencing a vertebral 
fracture (p = 0.007). Nonvertebral fractures were 
not significantly different. Adverse effects were 
significantly greater for teriparatide in the follow-
ing categories: nausea 17 versus 8% for alendro-
nate (p = 0.007), dyspnea 7 versus 3% (p = 0.028), 
insomnia 6 versus 1% (p = 0.017), viral infection 2 
versus 0% (p = 0.023) and hypercalcemia 21 ver-
sus 7% (p < 0.001). Alendronate was significantly 
greater for weight loss 4 versus 0% (p = 0.002). 
Although bisphosphonates are commonly recom-
mended for treatment of GIO, teriparatide has 
demonstrated superiority at the hip and spine, 
with a possible reduction in fractures compared 
with alendronate.
Hormone therapy was compared with calcitriol 
in 20 premenopausal women treated for sys-
temic lupus erythematous with chronic steroids 
[52]. Women in the trial had received more than 
10 mg of prednisone daily and were randomized 
to conjugated estrogen 0.625 mg daily days 1–21 
of menstrual cycle and medroxyprogesterone ace-
tate (MPA) 10 mg daily days 11–21, or calcitriol 
0.5 µg daily. The average age of women at base-
line was 37 years, they had experienced amen-
orrhea for 2 years, had osteopenia (LS BMD: 
0.9 g/cm2 and hip BMD: 0.7 g/cm2) and all 
participants took calcium 1000 mg daily. After 
24 months, LS BMD decreased significantly 
by 1.74% (p < 0.05) in the calcitriol group but 
increased by 2% in the hormone therapy group 
(p < 0.05). The difference between groups at the 
LS was significant (p < 0.03). No fractures were 
reported over the course of the study. In women 
with lupus, hormone therapy was superior to 
 calcitriol for treatment of GIO.
Overall, FDA-approved treatments for osteo-
porosis are superior to vitamin D alone. Teri-
paratide and zoledronic acid have demonstrated 
superiority to oral bisphosphonates in women 
with GIO. Therapy should be based on ACR 
recommendations, patient history and prescriber 
preference.
Cystic fibrosis
With the increase in life expectancy for cys-
tic fibrosis (CF) patients comes an increase in 
the development of CF-related bone disease 
[53]. Although the precise mechanism of bone 
loss in CF patients is unknown, several factors 
probably contribute, including lower peak bone 
mass due to poor nutrition and physical activ-
ity, delayed puberty and hypogonadism, use of 
gluco corticoids, and inflammatory cytokines. 
Due to the increase in osteoporosis in this popu-
lation, studies have been conducted to evaluate 
 appropriate treatments in these younger patients.
A randomized, double-blind, placebo-con-
trolled trial of alendronate 10 mg daily was carried 
out in CF patients with a T-score of less than or 
equal to -1 at the spine or FN for 12 months [54]. 
Forty-eight patients were included and equally 
divided between the two groups. The alendronate 
group contained nine females and the placebo 
group contained 14. The average age of the par-
ticipants was 27.5 years, the average LS T-score at 
baseline was -1.785 and the Z-score was -1.695. 
All subjects received 800 IU of vitamin D and 
1000-mg calcium daily. The alendronate group 
demonstrated a significant increase in BMD at 
the hip (4.9 vs -1.8%; p < 0.001) and spine (2.8 
vs -0.7%; p = 0.003) compared with placebo. 
The authors noted a greater BMD response at 
the spine in male subjects than female subjects. 
No new vertebral fractures occurred during the 
study period. While placebo subjects with base-
line osteopenia continued to experience bone loss 
after 1 year, subjects taking alendronate experi-
enced a significant increase. This demonstrates 
the efficacy of oral bisphosphonates in the CF 
population; however, as adverse events were not 
discussed, safety in this younger population still 
needs to be evaluated.
Alendronate 70 mg weekly was evaluated in 
56 patients, including 22 women with CF and 
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a BMD T-score less than -1 in a randomized, 
double-blind, placebo-controlled 12-month 
trial [53]. All women also took vitamin D 800 IU 
daily and calcium 500 mg from supplement ation 
and 500 mg from the diet daily. The average age 
of the participants was 29 years and the aver-
age T-score at baseline in the LS was -1.6. After 
12 months, LS BMD increased by 5.2% in the 
alendronate group (n = 10) and decreased by 
0.08% in the placebo group (n = 12), p < 0.001. 
Hip BMD increased by 2.1% in the alendronate 
group and decreased by 1.3% in the placebo 
group, p < 0.001. There was no significant dif-
ference in the development of new vertebral frac-
tures over the course of the study. Adverse events 
were similar in both groups. This study further 
demonstrates the role of alendronate in improv-
ing BMD in patients with CF and demonstrates 
no additional safety risks in this population.
Although data are limited to small studies with 
one active ingredient, the future looks promising 
for the use of oral bisphosphonates in patients 
with CF and demonstrated bone loss. Additional 
research is needed to evaluate the long-term risks 
in this population.
Kidney transplantation
Fracture risk for kidney transplant patients is as 
high as 10% within the first 2 years, probably 
due to the high doses of corticosteroids used to 
prevent rejection. Post-transplant osteodystro-
phy is also due to the comorbity of diabetes in 
many transplant patients, along with high doses 
of loop diuretics. Zoledronic acid was evaluated 
in 20 patients for prevention of bone loss fol-
lowing kidney transplantation in a randomized, 
double-blind, placebo-controlled trial [55]. All 
patients received methylprednisolone as part of 
their antirejection regimen, with a cumulative 
dose of 3 g over the course of the study. They also 
received calcium citrate 1000 mg daily and daily 
injections of 0.25–0.5 µg of activated vitamin D. 
Participants were randomized to either zoledronic 
acid 4 mg iv. at 2 weeks and again at 3 months 
after transplant (n = 10) or placebo (n = 10). The 
average age of participants was 49–55 years and 
four out of the ten in each group were women. 
LS Z-scores were -0.5 to -1 and FN Z-scores 
were -0.8 to -1.1 at baseline. At 6 months, the LS 
Z-score decreased by 0.27, while the zoledronic 
acid group increased by 0.23. The authors report 
that this was a significant difference from baseline 
in each group; however, p-values were not listed. 
At the FN, the Z-score decreased by 0.57 in the 
placebo group (listed as significant) and remained 
stable (a 0.02 increase) in the zoledronic acid 
group. A follow-up study 3 years after transplant 
was performed and the Z-score in the placebo 
group increased from -1.3 at 6 months to -0.2 at 
3 years (p = 0.021) and from -1.6 to -1.2 in the 
zoledronic acid group (p = 0.044) [56]. Overall, 
the effect of zoledronic acid was temporary as 
all groups experienced improvement in BMD 
after 3 years. Two vertebral fractures occurred 
in each group over 3 years. These results suggest 
that osteoporosis prevention may not be required 
in kidney transplant patients due to limited 
long-term benefit on BMD or fractures.
iv. ibandronate was evaluated in 80 patients 
(average age: 43 years) after kidney transplant, 
a population which included 13 premenopausal 
women [57]. Dietary counseling to encourage 
1000 mg of daily calcium consumption was 
provided and supplementation of 500 mg was 
supplied for those with dairy intolerance. The 
treatment group received ibandronate 1 mg iv. 
before transplant (lower dose adjusted for renal 
function) and 2 mg iv. every 3 months after trans-
plant for a total of four infusions over 12 months 
(n = 36 with six premenopausal women), while 
other subjects were randomized to placebo 
(n = 36 with seven premenopausal women). All 
patients received cyclosporine, prednisone (aver-
age: 12–13 mg/day) and mycophenolate mofetil 
to prevent rejection. At baseline, LS T-score was 
-0.7 and FN T-score was -0.7. BMD decreased in 
both groups at the LS after transplant; however, a 
significantly greater percentage of bone loss was 
noted in the control group (-0.9% ibandronate vs 
-6.5% control; p < 0.0001). Different responses 
at the FN were also noted (+0.5 ibandronate vs 
-7.7% control at the FN; p < 0.0001). Benefits of 
ibandronate were noted by the authors to occur at 
all sites in the subgroup of premenopausal women. 
Adverse effects of ibandronate included bone pain 
and flatulence. This study demonstrated a ben-
efit for frequent dosing of an iv. bisphosphonate, 
although the long-term benefits have not been 
elucidated.
In the setting of kidney transplant, data are 
limited to support the use of any osteoporosis 
treatment, including iv. bisphosphonates.
Other
In athletes with resulting menstrual cycle irregu-
larities, cyclic MPA 10 mg daily for 10 days per 
month was evaluated with and without calcium 
1000 mg/day supplementation in a 12-month, 
randomized, double-blind, placebo-controlled 
trial. Women aged 21–45 years (n = 61) were 
randomized to four groups (n = 16 in both MPA 
groups, n = 15 in active calcium group and n = 14 
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in placebo group). LS BMD was increased by 
1.7% (p = 0.004) in both MPA groups, while 
the calcium alone group experienced no change 
in BMD [58]. Calcium supplementation may be 
sufficient to minimize bone loss in female ath-
letes with menstrual irregularities; however, addi-
tional evidence is needed to determine the role of 
hormone therapy in this population.
Hormone therapy for treatment of hypo-
gonadism associated with b-thalassemia major was 
evaluated in an observational study of 60 patients, 
including 30 women [59]. The average age of the 
women was 19 years. Women were divided into 
three groups: those receiving hormone therapy 
with 17-b estradiol 50 µg daily for 21 days each 
month and MPA 10 mg for 11 days each cycle 
(n = 10), those untreated (n = 10) and a control 
group of women without  b-thalassemia (n = 10). 
Women with b-thalassemia had decreased spine 
BMD compared with controls (p < 0.001), 
while estradiol/medroxyprogesterone-treated 
women had increased BMD at the LS com-
pared with untreated women with  b-thalassemia 
(p < 0.001). At the FN, the untreated 
women had significantly lower BMD than 
both the control group (p < 0.001) and the 
estradiol/medroxyprogesterone-treated group 
(p < 0.001). The authors concluded that osteo-
porosis is found at the LS and FN in untreated 
women with thalassemia, while osteoporosis is 
only present in the LS for women treated with 
estradiol/medroxyprogesterone. The application 
of these results is limited at this time due to the 
limited population studied.
Various osteoporosis treatments were com-
pared in women with ovarian failure after a 
stem cell transplant [60]. Bone loss after stem 
cell transplant is often associated with ovarian 
failure. The authors report that standard treat-
ment after stem cell transplant is for women 
to receive calcium/vitamin D and hormone 
replacement. Those who go on to develop osteo-
porosis are then treated with bisphosphonates. 
Four groups of 15 women were randomized 
to calcium 1000 mg/vitamin D 800 IU once 
daily alone, estradiol 2 mg daily with dihydro-
progesterone 10 mg for 14 days per month with 
calcium/vitamin D, risedronate 35 mg weekly 
with calcium/vitamin D or zoledronic acid 4 mg 
iv. monthly for 3 months with calcium/vitamin 
D for 12 months. The average age of women 
in the trial was 26 years and baseline LS BMD 
was -1.4, while FN BMD was -1.5. The cal-
cium/vitamin D group experienced a signifi-
cant decrease in BMD from baseline at the spine 
(-4.3%; p < 0.05) and FN (-4.2%; p < 0.05), 
while the hormone therapy group remained 
stable at all sites. The risedronate group dem-
onstrated a significant increase in BMD at the 
LS (5.8%; p < 0.05) and the zoledronic acid 
group demonstrated a significant increase at the 
LS (8.6%; p < 0.01) and FN (5.4%; p < 0.05). 
Both bisphosphonates were significantly differ-
ent from the calcium/vitamin D and hormone 
treatment groups at both sites (p < 0.05), while 
the zoledronic acid group experienced a signifi-
cantly greater increase in BMD at the FN than 
the risedronate group (5.4 vs 1.2%; p < 0.0001). 
Vertebral fractures were found in five women at 
baseline and three additional vertebral fractures 
occurred during the 12 months. The study was 
not powered to detect a difference in fractures. 
Adverse effects occurred in six out of 15 women 
in the hormone treatment group (headache and 
breast tenderness), three out of 15 women in 
the risedronate group (gastric pain) and flu-like 
symptoms in 12 out of 15 women in the zole-
dronic acid group. Overall, nonhormonal osteo-
porosis treatment proved superior to placebo or 
hormone replacement in women with ovarian 
failure after stem cell transplant. Either oral or 
iv. bisphosphonates may prove beneficial in this 
population, although further studies on fracture 
reduction should be carried out to determine 
overall benefit.
Women with endometriosis who were treated 
with gonadotropin-releasing hormone agonists 
were randomized to treatment with parathyroid 
hormone 40 µg subcutaneously daily (n = 20) 
or placebo (n = 20), and followed for 6 months 
[61]. Subjects (average age: 30 years) remained 
on nafarelin 200 µg intranasally twice daily 
throughout the study and were encouraged 
to maintain daily consumption of calcium at 
1200 mg through diet or supplements. LS BMD 
was 0.8 g/cm2 and FN BMD was 0.9 g/cm2 at 
baseline. At the LS, BMD decreased by 2.8% 
from baseline (p < 0.001) in the placebo group, 
while BMD in the treated group increased by 
3.4% (p = 0.01). The difference between the two 
groups reached significance (p < 0.001). No dif-
ferences were noted between the groups at the 
FN. Adverse effects in the parathyroid hormone 
group were reported as follows: emotional insta-
bility 40%, nausea 35%, arthralgia 30%, weight 
gain 15% and hair loss 10%. Due to the limited 
evidence in this population and comparison with 
placebo rather than other active treatments, no 
recommendations can be made at this time. Mul-
tiple adverse events were associated with para-
thyroid hormone, which may also limit its use in 
this population.
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Alendronate was evaluated in patients with 
Crohn’s disease and low BMD (T-score less 
than -1 in either the hip or spine) in a random-
ized, double-blind, placebo-controlled trial of 
32 patients over 12 months [62]. Subjects were 
randomized to alendronate 10 mg daily (n = 17) 
or placebo (n = 15), with vitamin D 400 IU daily 
and calcium if dietary intake was below 1000 mg 
daily. LS BMD increased by 4.6% in the alendro-
nate group and decreased by 0.9% in the placebo 
group (p < 0.01). BMD was noted to increase 
in premenopausal, as well as postmenopausal 
women. In women with low T-scores and Crohn’s 
disease, this study supports the use of alendronate 
to improve BMD. Additional studies are needed 
to ascertain the benefits for fracture prevention.
Calcitonin was evaluated in 28 premenopausal 
women with recent oophorectomy to prevent bone 
loss [63]. Women were randomized to 100 IU of 
salmon calcitonin or placebo intramuscular every 
other day starting 7 days after oophorectomy for 
6 months, then all women were given active cal-
citonin for an additional 6 months. Addition-
ally, the participants received calcium 500 mg 
twice daily. While the placebo-treated patients 
experienced a significant decrease in BMD after 
12 months, the calcitonin-treated group did not 
see a decline. Due to the small and limited stud-
ies, calcitonin cannot be recommended for pre-
vention of bone loss in premenopausal women 
with oophorectomy.
Conclusion
Osteoporosis diagnosis and management is clearly 
defined for postmenopausal women, where the 
risks for fractures and benefits of treatment have 
been well studied. Osteoporosis discovery and 
treatment in younger, premenopausal women 
is less well defined due to the minimal risk of 
fractures and lack of large RCTs. Premenopausal 
osteoporosis is often a result of an underlying 
condition or medication, and management is 
Executive summary
Background
• Healthy premenopausal women experience a 0.25–1% loss in bone mineral density (BMD) annually after reaching peak bone mass, 
and osteoporosis may be seen in 0.5% of premenopausal women.
• Many cases are due to secondary causes; however, the remaining cases are idiopathic in nature.
Diagnosis
• The International Society for Clinical Densitometry advocates the use of Z-scores rather than T-scores to determine BMD “below the 
expected range for age.”
• The Z-score combined with risk factors, including a history of fragility fracture, is then used to make a diagnosis of osteoporosis in 
younger women.
Osteoporosis prevention in young women
• The National Osteoporosis Foundation recommends that women aged 18–50 years should consume 1000 mg of calcium and 600 IU of 
vitamin D daily.
• This, along with regular weight-bearing exercise, avoiding smoking and alcohol, and limiting caffeine consumption, are important 
lifestyle factors to prevent or minimize osteoporosis in young women.
Anorexia nervosa
• Hormone therapy does not demonstrate benefit in young women with anorexia nervosa.
• The strongest evidence for improvement of BMD is for weight gain and return of the menstrual cycle.
Breast cancer
• The overall data for bone loss associated with breast cancer and chemotherapy support the role of bisphosphonates (particularly the 
intravenous bisphosphonate zoledronic acid).
• The safety profile is similar to that for postmenopausal women, although risks in pregnancy and breastfeeding have not been 
established.
Glucocorticoid-induced osteoporosis
• In younger women with glucocorticoid-induced osteoporosis, recommendations from the American College of Rheumatology and the 
International Osteoporosis Foundation/European Calcified Tissue Society are available.
Cystic fibrosis
• Alendronate has demonstrated benefit in young women with cystic fibrosis and demonstrated bone loss.
• Additional research is needed to evaluate the long-term risks in this population.
• Data are limited to support the use of any osteoporosis treatment in other conditions not listed above.
• The evidence for treatment of osteoporosis in premenopausal women is not nearly as robust as that for postmenopausal osteoporosis. 
Data are limited to recommend osteoporosis treatment outside the setting of a previous fracture or an underlying secondary cause.
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